IDEXX Laboratories, Inc. develops, manufactures, and distributes a wide range of products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets globally. The company operates through various segments including CAG, Water Quality Products, LPD, and others. IDEXX provides point-of-care veterinary diagnostic products, such as instruments, consumables, and rapid assay test kits. It offers veterinary reference laboratory diagnostic and consulting services, along with practice management and diagnostic imaging systems for veterinarians. Furthermore, it supplies health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for the biomedical research community. Additionally, the company delivers diagnostic and health-monitoring products for livestock, poultry, and dairy and tests for water microbiological contaminants. In the human point-of-care medical diagnostics market, IDEXX offers point-of-care electrolytes and blood gas analyzers, as well as SARS-CoV-2 RT-PCR products; it also provides in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, and SNAP rapid assay test kits. Moreover, IDEXX markets tests such as Colilert, Colilert-18, and Colisure for detecting total coliforms and E. coli in water, along with other specialized products like Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray. The company supports independent veterinary clinics and corporate groups with veterinary software and services while distributing its products through various sales and technical service teams, distributors, and other resellers. The earnings per share (EPS) is reported at $10.77 indicating the company's profitability on a per-share basis. The operating income ratio is 0.29 indicating the company's operational profitability margin. The company reported an income before tax of $1,109,831,000.00 showcasing its pre-tax profitability. The net income ratio is 0.23 reflecting the company's profitability margin, and the EBITDA is $1,275,840,000.00 a key indicator of the company's operational profitability. In terms of stock performance, the stock is priced at $515.55 positioning it in the higher-end market. The stock has an average trading volume of 842,722.00 indicating moderate liquidity. With a mid-range market capitalization of $41,461,510,545.00 the company is a steady performer. IDEXX is a key player in the Medical - Diagnostics & Research industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth.